Overall, these trials showed that Myozyme provides a considerable benefit when used in Pompe disease, especially when started early in the disease course. ERT (Myozyme) acts by restoring lysosomal GAA activity, resulting in the stabilization and restoration of cardiac and skeletal muscle function. In a previous trial, patients started receiving Myozyme at the age of one year twice a week [7]. The gene discussed is GAA; the disease is glycogen storage disease II.